NCT07268170Enrolling by invitationPhase 2/3
Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease
Heart Rate Control: Betablockers or Ivabradine Therapy Before Cardiac Computed Tomography
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to describe which type and dose of commonly used heart rate reducing drugs (metoprolol, atenolol, or ivabradine) has the swiftest heart rate reduction from baseline in patients aged 30 to 80 years with a heart rate \> 65 beats per minute undergoing cardiac computed tomography for the evaluation of coronary artery disease. The main question it aims to answer is • Which type of heart reducing drug and dose has the swiftest heart rate reduction before cardiac computed tomography?
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- Dec 2025
- Primary completion date
- Sept 2028
- Lead sponsor
- Gødstrup Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07268170
- EU CT number
- 2025-522741-21-00
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 350
- From Dec 2025 to the primary completion date, Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous percutaneous coronary intervention (with or without stent)
- Previous CABG
- Regular treatment with beta-blockers
- Regular treatment with ivabradine
- Regular treatment with Cordarone
- Concurrent treatment with potent inhibitors of CYP3A4
- Concurrent treatment with potent inhibitors of MAO inhibitors,
- Concurrent treatment with potent inhibitors of CYP2D6 inhibitors
Other illness
- Heart rate \> 100 bpm
- Known ischemic heart disease
- Acute coronary syndrome
- Known allergy to beta-blockers
- Known allergy to ivabradine
- Known allergy to used radiographic contrast agents
- Sick sinus syndrome
- Severe heart failure
- Severe metabolic conditions
Lab values
- Heart failure with systolic left ventricular ejection fraction \< 45%
- Reduced kidney function with estimated glomerular filtration rate (eGFR) \< 40 ml/min
- Regular treatment with non-dihydropyridine calcium antagonists (Verapamil and Diltiazem)
- Concurrent treatment with potent inhibitors of intravenous calcium antagonists type I or III
Age
- Age \> 80 years
- Age \< 30 years
Other
- BMI \> 35
- Pacemaker
- Pregnant, including potentially pregnant, or breastfeeding (potentially pregnant patients will undergo pregnancy testing)
- Contraindications for beta-blockers or ivabradine:
- Severe asthma
- Severe COPD
- Sinoatrial block (1st degree AV block)
- Advanced AV block (2nd or 3rd degree)
- Hypotension (systolic blood pressure \< 110 mmHg)
- Severe restrictive cardiomyopathy
- Severe aortic stenosis
- Severe circulatory disturbances
- Untreated pheochromocytoma
Who the study is looking for
- Individuals who are to undergo Cardiac CT
- Sinus rhythm with heart rate \> 65 bpm on ECG
- Competent patients who have given written informed consent
Age in the registry: 30 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Clinic of Ischemic Heart Disease Coordinator of this site? Confirm its status | Herning | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.